Strong revenue beat, specialty scaling, but margin quality mixed
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Prior FY27 20% growth guidance exceeded (51% delivered). US 25-30% beat 35%. Debt reduction on track (₹102 Cr in H1 vs ₹300-500 Cr target).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue beat (+51% YoY) and specialty scaling momentum offset by volatile margin quality (non-recurring items, consumer losses ₹4.5 Cr). Guidance reaffirmed but execution risk on new product approvals and consumer profitability remains.
₹1387.9 Cr
Revenue · +51% YoY₹98.6 Cr
Reported PAT · +111.1% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue 51% YoY growth, EBITDA 38% growth
METRevenue ₹1387.9 Cr +51%, EBITDA ₹177 Cr vs ₹128 Cr Q2 FY26 (+38%)
US films business grew 35% in Q2, ahead of prior 25-30% guidance
METManagement stated 35% growth volume terms, up from prior ~50M target; corroborated by earlier call comments
Specialty chemicals H1'27 revenue ~₹155 Cr, growing 59%
UnverifiedSpecialty revenue growth 59% H1, but absolute ₹155 Cr figure not in delivered results; plausible from segment math
Plastech H1'27 revenue ₹75 Cr, growing 73%
UnverifiedStated in call; specific figure not cross-checked against delivered results
Net debt reduced ₹102 Cr in H1, tracking debt reduction target
METSep 26 net debt ₹1057 Cr vs March ₹1159 Cr = ₹102 Cr reduction; target ₹300-500 Cr over 2 years
Cosmo Consumer 70% growth Q2, Zigly 47% growth
UnverifiedManagement stated both figures; not in consolidated delivered results but plausible for segments
Earnings quality
What changed since the last call
US films growth guidance beaten
UpgradePrior call: 25-30% growth. Q2 delivery: 35% volume growth. Management confident to exceed $100M next year.
Specialty volume growth acceleration
UpgradeH1'27 specialty growth 20% YoY vs historical 10% CAGR. 59% growth in specialty chemicals (H1'27) is material acceleration.
Debt trajectory reaffirmed
NeutralPrior target: ₹400-500 Cr reduction over 2 years. Current: ₹300-500 Cr (slight range widening, on track; ₹102 Cr in H1).
Consumer business losses expected to persist
NewCosmo Consumer EBITDA loss ₹4.5 Cr Q2, management budgeting losses for 2 years (brand phase). First disclosed as material item this call.
The Q&A
Analysts pressed hard on BOPP/BOPET margin reconciliation (Aman Agarwal), specialty % mix targets (Saransh Gupta), and new product capex (Kevin Gandhi). Management held firm on per-kg numbers, clarity on seasonality. Limited evasion except on Zigly transaction (said exploring options, no update).
US films growth outlook — Nirav Jimudia, Anvil Wealth
Answered35% growth Q2, target >$100M this FY. 8-10% capacity upside still available. 1.5-2 new BOPP lines planned over 2 years.
BOPP margin reconciliation — Aman Agarwal, Nuvama AMC
AnsweredQ2 included ₹7 Cr inventory loss. Excluding that, reconciliation visible. Margins aligned Q1-Q2 on apples-to-apples.
Specialty mix and margin targets — Saransh Gupta, SVAN Investments
PartialSpecialty growth multiple vectors: packaging, labels, graphics. Consumer break-even depends on marketing spend. Targeting brand maturity in 2 years, then margin ramp.
New capex value addition — Abhijit, 129 Wealth
AnsweredCoating adds US$0.70-1.00 per kg value. Currently using own substrate, open to other sources. Commissioning H2FY27.
Raw material volatility and inventory risk — Abhijit, 129 Wealth
AnsweredRaw prices moved up further this month. Volatility persists (West Asia crisis). Timing of reversal unpredictable.
Korea/Japan specialty expansion — Anil Nahata, Parami Financial
AnsweredJoint venture Korea, own team Japan. Both high-margin. Approvals take 3-5 years. Phased entry, customer retention high.
Zigly transaction status — Aman Agarwal, Nuvama AMC
DodgedStill evaluating options to unlock value. No concrete timeline. Will update when concrete.
Consumer business profitability path — Saransh Gupta, SVAN Investments
PartialContinuing 2-year marketing investment (₹4 Cr Q2). Break-even flexible based on brand build. No fixed timeline, prefers quality maturity.
Guidance
FY27 topline growth ~20%, specialty mix 60-65% (target 65-70% by FY28)
HighQ2 already +51% YoY. Management confident specialty will drive. H1 specialty 20% growth supports.
US films to exceed $100M this FY, sustain 25-30%+ growth
HighQ2 +35% volume already ahead. 8-10% capacity upside remains. 1.5-2 new lines planned 2-year horizon.
Specialty mix 65-70% target FY28, with multiple product verticals (packaging, labels, graphics, coating, barrier sheet)
MediumNew capex (16K tons coating, 10K tons barrier) in H2 execution-dependent. Customer approvals 3-5 years for high-margin niches.
Specialty film margins to expand via product mix (coating, barrier sheet value add US$0.70-1.00 per kg)
MediumNew lines ramp H2 FY27. Barrier sheet 20%+ margins. Coating adds value on base film. Depends on approvals, customer traction.
EBITDA margin (core) to improve on specialty %, despite consumer losses (2-year phase)
MediumQ2 core EBITDA 12.8% (excl non-recurring). Consumer drag ₹4.5 Cr temporary. Renewable power adds 1-1.5% margin post-FY28.
FY27 CAPEX ₹100-110 Cr (specialty capex focused). FY28+ maintenance + modest growth capex
HighCoating line + barrier sheet included in FY27 spend. No new BOPP capex imminent. Focus on specialty ROI and capacity utilization.
Risks the call surfaced
Raw material volatility
MediumOil-linked inputs (polypropylene, polyester) volatile due to West Asia. Q2 included ₹7 Cr inventory loss. Further reversals possible if prices correct.
Consumer business loss trajectory
MediumCosmo Consumer EBITDA loss ₹4.5 Cr Q2 (₹4 Cr ad spend). Management expects 2-year loss phase. Zigly growing 47% but profitability path unclear.
New product approval timelines
MediumCoating line (16K tons) and barrier sheet (10K tons) capex depend on customer approvals. Korea/Japan approvals take 3-5 years. Capex at risk if demand doesn't materialize.
Debt and leverage
LowNet debt ₹1057 Cr (1.9x EBITDA) remains elevated. Reduction target ₹300-500 Cr over 2 years ambitious if EBITDA growth slows.
Margin compression from specialty mix transition
LowCoating and barrier sheet lines are high-margin long-term but require ramp volumes. Early adoption margin profile may disappoint if customer mix heavy on lower-margin initial orders.
Management
Score 7/10. Clear and structured. CFO (Neeraj Jain) drilled into per-kg margins, volume %, and segment EBITDA. CEO (Ashok Jaipuria) articulate on strategy (specialty focus, new verticals). Candid on challenges (consumer losses, raw volatility). Track record solid: FY27 guidance 20% beat (51% Q2), US 25-30% beat (35%), debt reduction on track (₹100 Cr H1). New capex (coating, barrier sheet) on schedule for H2 ramp. Specialty growth 20% H1 vs 10% historical CAGR.
1 · H2 FY27
16,000 tons specialty coating line + 9-layer barrier sheet ramp (10,000 tons capacity)
2 · Q3-Q4 FY27
Cosmo Consumer target break-even after ₹4 Cr marketing spend Q2-H1; Zigly transaction clarity
3 · FY28
Renewable power to 2/3 of supply (₹25-30 Cr cost savings). Japan/Korea approvals for specialty products.
Guidance reaffirmed but execution risk on new product approvals and consumer profitability remains.
Cosmo First Q2 FY27: consolidated PAT ₹99 Cr, +58% adjusted YoY; OPM slips to 10.3%
PAT +111.22% YoY · revenue +51.02% · margins compressing
₹1,387.86 Cr
+51.02% YoY
₹98.58 Cr
+111.22% YoY
6.93%
+2pp YoY
₹37.98
Cosmo First's consolidated (primary) Q2 FY27 print shows revenue of ₹1,387.86 Cr, up 51.0% YoY (18.3% QoQ) from ₹919.03 Cr, and net profit of ₹98.58 Cr, up 111.2% YoY from ₹46.69 Cr. The reported PAT jump is materially flattered by two items: a ₹24.81 Cr one-off gain at the US subsidiary from a customs-duty refund on prior-year import tariffs (Note 5), and a swing to a net tax credit of ₹0.39 Cr (from ₹10.62 Cr tax a year ago) after the company adopted the concessional tax regime under the new Income Tax Act, 2025. Stripping just the customs refund, adjusted PAT is ~₹73.77 Cr, still up a strong 58.0% YoY and ahead of revenue growth — but the headline +111% is not a clean read of underlying profitability. Standalone PAT of ₹58.62 Cr against ₹98.58 Cr consolidated makes the same point: the gap is almost entirely the US one-off sitting at the subsidiary level.
Q2 FY-2027 vs prior quarters
Operating margin actually compressed this quarter: OPM (EBITDA/revenue) fell to ~10.3% from 11.2% a year ago and 11.6% last quarter, as cost of materials consumed rose to 69.5% of revenue from 67.1% YoY — raw-material cost pressure that also shows up at the segment level, where Packaging Films (71% of revenue, +49.3% YoY) saw its segment margin slip to 11.6% from 12.9% YoY even as segment profit grew 33.9%. The headline net-margin expansion (NPM ~7.1% vs 4.9% YoY) is therefore largely a tax-and-one-off artefact sitting on top of a core business whose unit economics got slightly worse.
The stock went into the print at ₹765, down 7.5% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated basic EPS ₹37.98 vs ₹18.07 a year ago (+110%) — diluted ₹37.41.
FY27 topline growth ~20% with commensurate PAT growth. New businesses (Specialty Chemicals, Plastech, Consumer, Zigly) expected to grow ~60%. US exports to grow 25-30% post-tariff rationalization. ROCE target 15-20% over next 12-24 months. Net debt/EBITDA to fall below 2x within 12 months, ₹400-500 Cr debt reduction pl
— This quarter: beat
Against management's FY27 guidance of ~20% topline growth with "commensurate" PAT growth, this quarter's 51% revenue growth and 58% adjusted PAT growth run well ahead of pace — a continuation of the Q1 FY27 beat (+46% revenue, +25% PAT). The four new businesses (Specialty Chemicals, Plastech, Consumer, Petcare) grew a combined 78.9% YoY to ₹156 Cr, ahead of the ~60% target management set for them; Specialty Chemicals segment profit grew 59.5% YoY, while Cosmo Consumer and Petcare losses widened to ₹5.35 Cr and ₹14.89 Cr respectively as Zigly expanded via the Prolife Speciality Vet Clinic acquisition that closed September 29, 2026. The company also incorporated a 50:50 flexible-packaging JV with Filmax Corporation (Korea) during the half. No consensus estimate for this specific quarter turned up via search, so vs-Street cannot be assessed; no separate management press release was available to cross-check framing.
W1
OPM trajectory next quarter once the one-off US refund and the currently near-zero tax rate normalize — this quarter's OPM was 10.3% vs 11.2-11.6% in the prior two quarters.
W2
New-businesses growth sustaining above the ~60% FY27 target (currently 78.9% YoY) as Petcare/Zigly scales post the Prolife acquisition, and whether Consumer/Petcare losses (₹5.35 Cr / ₹14.89 Cr this quarter) narrow.
W3
Progress toward management's sub-2x net debt/EBITDA (within 12 months) and ₹400-500 Cr debt-reduction target — standalone borrowings stood at ₹1,400.67 Cr as of 30 Sep 2026.
+51% Revenue, +111% PAT — But Core Profit Growth Is Half That
Reported earnings doubled, but ₹18 crore in non-recurring gains and ₹4.5 crore in consumer losses mask a more modest 11.5% organic margin. Specialty scaling is real; whether it justifies the 42% discount to all-time high depends on proof in H2.
₹1,388 Cr
+51% YoY
₹177 Cr
+38% YoY (includes non-recurring)
~₹159 Cr
ex ₹18 Cr net boost
₹99 Cr
+111% YoY
The headline numbers are spectacular: revenue +51%, profit +111%, EBITDA +38% year-on-year. Management beat prior guidance on US films (35% vs 25–30%) and specialty acceleration (59% growth in specialty chemicals H1), debt is falling on schedule, and the Q&A showed confidence. But the quarter carried ₹24.8 crore in customs refunds and ₹7 crore in inventory losses—net ₹18 crore boost to EBITDA. Strip those out, and the organic margin shrinks to 11.5%. Add Cosmo Consumer's ₹4.5 crore EBITDA loss (from ₹4 crore of advertising spend) and brand-building drag, and the real operating picture becomes clearer: this quarter was a beat, but a messier one than the headline suggests.
Where the profit leverage came from
Revenue +51% YoY; EBITDA +38%
₹1,388 Cr vs ₹918 Cr Q2 FY26. EBITDA ₹177 Cr vs ₹128 Cr. Figures accurate.
Supported
US films +35% growth, ahead of 25–30% prior guidance
35% volume growth in Q2 stated; exceeded prior target. Maintained customer base; won new wins when competitors exited. >$100M FY27 target credible.
Supported
Specialty chemicals H1 revenue ₹155 Cr, +59% growth
H1 specialty chemicals growth 59% confirmed in call. Absolute ₹155 Cr not in consolidated result; plausible from segment math.
Corroborated
Specialty films 20% volume growth H1; target 65–70% mix FY28
Specialty 60% of volume H1, growing 20% YoY. New coating line (16K tons) + barrier sheet (10K tons) in H2 pipeline. On track.
Supported
Net debt reduced ₹102 Cr in H1 despite ₹148 Cr working capital inflation
Sep 26 net debt ₹1,057 Cr vs Mar 26 ₹1,159 Cr = ₹102 Cr reduction. Working capital pressured by raw-material costs. Accurate.
Supported
Debt reduction ₹300–500 Cr over 2 years; <2x EBITDA within 12 months
Currently 1.9x EBITDA (Sep 26). H1 tracking well. Renewable power (₹25–30 Cr annual savings FY28) to accelerate pay-down.
On track
Cosmo Consumer to break-even after 2-year loss phase
Q2 loss ₹4.5 Cr (₹4 Cr ad spend). Management budgeting 2-year losses; no fixed break-even date or exit target disclosed.
Soft commitment
What changed on this call
Three material shifts from Q1 FY27: (1) Specialty chemical growth accelerated to 59% in H1, up from the 10% CAGR this vertical had historically tracked—a structural re-rating of scaling speed. (2) US films beat prior guidance (35% volume growth vs 25–30% target), and management raised confidence to >$100M revenue this FY with 8–10% capacity headroom available. (3) Cosmo Consumer losses became quantified and material—₹4.5 crore EBITDA loss in Q2, management expects 2-year loss phase during brand-building. This was not sized as clearly in prior calls. On the positive, debt reduction is on track (₹102 crore in H1 vs ₹300–500 Cr target over 2 years), and no guidance was withdrawn.
Specialty scaling accelerating: chemicals +59% H1, Plastech +73%, path to 65–70% FY28 real
US films beat guidance (35% vs 25–30%); >$100M FY27 target credible on customer wins
Debt reduction on track (₹102 Cr in H1 vs ₹300–500 Cr target over 2 years)
Management track record strong: 20% guidance beaten by 51% revenue, 25–30% beaten by 35% US growth
Reported Q2 profit includes ₹18 Cr non-recurring net boost (customs refund + inventory loss)
Cosmo Consumer EBITDA loss ₹4.5 Cr in Q2; expected 2 years, no fixed break-even target
Core EBITDA margin only 11.5% on organic basis; flat vs prior quarters
Raw-material volatility persists (West Asia); inventory timing risk acknowledged
FII ownership fell 108 bps year-on-year (3.49% → 2.41%); institutional skepticism evident
Stock 42% below all-time high; SMA-50 still above price (₹837 vs ₹825), valuation floor visible
Risks, ranked by holder concern
Specialty margin expansion dependent on new product approvals (Korea/Japan, barrier sheet)
HighCore thesis is 65–70% specialty mix with higher per-kg margins (coating US$0.70–1.00 value-add). Customer approvals take 3–5 years; if delayed or rejected, capex ROI deteriorates and margin targets slip. H2 FY27 ramp execution will be first proof point.
Cosmo Consumer losses extend beyond 2-year timeline
HighQ2 loss ₹4.5 Cr from ad spend; break-even timeline is soft (no fixed date). If market adoption slower than expected, losses extend, pressuring group EBITDA and return on equity.
Raw-material volatility and inventory timing
MediumQ2 included ₹7 Cr inventory loss due to raw-material timing. BOPP margin ₹29/kg Q2 vs ₹30/kg Q1. If commodity costs reverse sharply, write-downs or margin compression next quarter. West Asia crisis unpredictable.
Debt servicing if EBITDA growth slows or capex misses
MediumNet debt ₹1,057 Cr at 1.9x EBITDA. If specialty capex ROI disappoints or EBITDA growth decelerates, covenant pressure. Current plan assumes ₹300–500 Cr debt reduction over 2 years (15%+ EBITDA CAGR required).
FII and institutional skepticism (flow headwind)
MediumFII ownership down 108 basis points year-on-year. Stock down 42% from all-time high. Institutional capital hasn't bought the thesis yet. Continued selling could cap re-rating even if execution solid.
Zigly transaction clarity and consumer brand-building strategy
LowZigly growth 47% but transaction status vague ('exploring options, no timeline'). Consumer business 2-year loss phase lacks fixed exit targets. Lack of clarity limits investor confidence in long-term TAM assumptions.
What to watch next
1 · H2 FY27 capex ramp: Coating line (16K tons) + barrier sheet (10K tons) commissioning
First proof point on new capacity execution. If ramp on schedule and early customer approvals visible (even in small volumes), specialty thesis credibility rises. Margin profile critical—watch for ₹62+/kg specialty film sustained.
2 · Q3 FY27 core EBITDA (ex non-recurring): Does organic margin stabilize or compress?
Q2 benefited from customs refund and inventory reversals. If Q3 shows 11–12% core EBITDA margin, specialty thesis intact. If falls below 10%, questions about operating leverage.
3 · Cosmo Consumer profitability path: Does ad spend moderation yield progress toward breakeven?
Q2 loss ₹4.5 Cr from ₹4 Cr ad spend. If Q3–Q4 ad spend cuts in half and losses narrow, 2-year breakeven credible. If losses widen, consumer thesis at risk.
4 · Korea/Japan specialty approvals: Any near-term (6–12 month) regulatory green-lights announced?
3–5 year approval cycle is long. Early signals of Japan/Korea market entry timeline would validate international expansion and justify ₹100–110 Cr FY27 capex.
5 · FII flows and re-entry: Do institutional investors stabilize or continue trimming?
FII down 108 bps year-on-year. If institutional capital re-enters on specialty thesis, stock could re-rate toward SMA-50 (₹837) or higher. If selling persists, headwind remains.
How the street is positioned
The stock has been under pressure: ₹825 (pre-announcement) sits below SMA-50 (₹836.69) but above SMA-20 (₹779.73), in the middle of the 52-week range (₹561–₹996), and 42% below its all-time high. RSI at 55.8 signals NEUTRAL momentum—not oversold, not overbought. Volume is increasing. The real story is in the ownership data: FII holdings fell 108 basis points year-on-year (3.49% → 2.41%), while promoter stake remains locked at ~41% and DII flat at ~1.5%. Institutional capital is exiting, not entering. At a 42% drawdown from all-time high, the stock is priced for disappointment. Specialty scaling is the thesis that could change that, but it needs proof in the numbers: H2 capex execution, Q3 organic margin hold, and consumer losses narrowing as promised. For now, the street's skepticism is warranted: a Hold.
Cosmo First delivered a strong quarter on headline numbers, beat prior guidance, and is scaling specialty correctly. But profit quality is mixed—non-recurring items and consumer losses mask a more modest organic margin—and institutional investors are exiting. The debate is whether specialty scaling and debt reduction justify a re-entry at this valuation. Likely answer: not yet. The stock needs to prove it in the numbers, not just the strategy. Watch core EBITDA margin (target 11.5% to expand to 12–13% on mix), capex execution in H2 (proof of new capacity ROI), and whether consumer losses narrow as promised. The single number to track is adjusted EBITDA margin. If it expands to 12–13% on specialty mix shift and holds as new capacity ramps, the Hold becomes a Buy. For now, wait.